Cannabis Law and Access in Ukraine

Ukraine passed its medical cannabis law in the middle of a war

July 2022. Russia's full-scale invasion was five months old. The Ukrainian parliament , the Verkhovna Rada , sat in Kyiv and passed Law No. 7457, legalising cannabis for medical and scientific purposes. The vote was 248 to 3. That number stays with me. I've read a lot of legislative histories at this point, and a 248-to-3 majority on a drug law, during wartime, is genuinely unusual.

It took another two years for the implementing regulations to catch up. That gap between a law passing and a system actually functioning is something I see in almost every jurisdiction , Australia included; and Ukraine is no exception. The short version is: the legal framework exists, it is real, and it is still being built out.

For Australian readers, this is not a guide to accessing cannabis in Ukraine. It's a look at how another country has structured its legal framework, the scheduling logic, the gaps, and what the reform actually changed. The comparison to our own Special Access Scheme and Authorised Prescriber pathway turns out to be more instructive than I expected.

What the 2022 law actually says

Law No. 7457, formally titled "On Amendments to Certain Legislative Acts of Ukraine Regarding Improving the Availability of Medicines Based on Narcotic Drugs and Psychotropic Substances," removed cannabis from the category of substances subject to an outright ban on medical use. Before that law, cannabis was listed under Ukraine's narcotics control framework, analogous to a Schedule 9 prohibited substance in the Australian Poisons Standard; with no lawful medical pathway at all.

The 2022 reform reclassified cannabis into a regulated medical access tier, placing it under a controlled-substance regime that requires licensing at every point in the supply chain: cultivation, processing, wholesale, and dispensing. It also created a prescription requirement for patient access. That prescription-only model has structural echoes of a Schedule 8 controlled drug framework, though the two systems are not directly comparable.

Critically, the law covers cannabis-derived products including those containing tetrahydrocannabinol (THC) and cannabidiol (CBD). The distinction between high-THC and predominantly-CBD preparations matters for regulatory purposes, much as it does under the TGA's own scheduling logic.

The implementation gap, and why it matters

Passing a law is the easy part. The Ukrainian Ministry of Health then had to produce subordinate regulations: licensing standards, cultivation limits, quality requirements (including what would function as Good Manufacturing Practice specifications, our equivalent is GMP), and the specific list of conditions for which prescription would be permissible.

Those subordinate instruments came through gradually across 2023 and into 2024. As of mid-2024, the Ukrainian regulatory framework nominally allows licensed domestic cultivation and production, as well as importation of approved cannabis-based medicines. But licensed producers operating at commercial scale inside Ukraine remain limited, partly because obtaining a cultivation licence requires satisfying security conditions that are; understandably, difficult to meet during an active armed conflict. Most of the country's territory in the east and south is either occupied or under active hostilities.

Honestly, I find it remarkable that the regulatory apparatus has progressed at all under these conditions. But the practical access picture for patients remains constrained.

The hemp side of the equation

Ukraine has a long history with industrial hemp, Cannabis sativa varieties bred for low THC content. Soviet-era agricultural records show Ukraine as one of the largest hemp producers in Europe for much of the 20th century. The post-Soviet legal environment criminalised most cannabis cultivation, but hemp for fibre and seed with THC below defined thresholds has operated in a separate regulatory lane.

The 2022 law did not fundamentally restructure the hemp framework, which is governed by agricultural rather than narcotics law. Low-THC hemp cultivation for industrial purposes was already permitted under separate legislation. What changed was the medical end of the spectrum.

CBD derived from compliant hemp sits in a grey zone in many jurisdictions. Ukraine's post-2022 framework attempted to address this by bringing CBD-containing products intended for medical use under the new prescription/licensing system; though enforcement consistency is, by most accounts, still developing.

Scheduling structure: a brief comparison

Australia uses the Poisons Standard (the SUSMP) to schedule substances. Cannabis and its preparations land across multiple schedules depending on concentration and formulation, from Schedule 4 (prescription only) through to Schedule 8 (controlled drug) for higher-THC products, with a Schedule 9 (prohibited) designation largely removed for approved medical preparations since the TGA's 2016–2017 rescheduling.

Ukraine's narcotics control legislation predates the 2022 reform and drew on the framework established by the 1961 UN Single Convention on Narcotic Drugs. The reform effectively created a new sub-category within the controlled-substances list rather than removing cannabis from it. The result is somewhat analogous to what Australia did in 2016, carving out a medical access pathway while retaining strict controls on supply, cultivation, and patient access.

What the Ukrainian framework does not yet have; at least not in a fully operational sense, is the equivalent of Australia's online SAS Category B portal, which by 2023 was processing tens of thousands of approvals per year. Digital prescription infrastructure and a nationally integrated pharmacy dispensing system for controlled substances are still works-in-progress in Ukraine.

THC, CBD, and what the chemistry means legally

The legal distinction between THC and CBD is worth understanding in any jurisdiction's framework. THC, delta-9-tetrahydrocannabinol; is the compound responsible for psychoactive effects and has historically driven most of the scheduling logic. CBD is non-intoxicating and was rescheduled in Australia in 2020 to allow low-dose over-the-counter access under Schedule 2 in specific circumstances.

In Ukraine's framework, both remain within the prescription/controlled system for medical-grade products. A cannabis product's chemical profile, including how much THC it carries relative to CBD and other minor cannabinoids, directly affects which tier of control it falls under. The full-spectrum versus isolate distinction matters here too: a CBD isolate containing no measurable THC sits differently in most regulatory systems than a full-plant extract.

(If you want the background on why the plant's chemistry is so relevant to scheduling logic, the piece on the endocannabinoid system is worth a read before going further into any jurisdiction's framework.)

Recreational use: still prohibited

The 2022 law was explicitly medical in scope. Recreational cannabis remains illegal in Ukraine under the Criminal Code. Possession of cannabis without a valid prescription can attract criminal penalties, and the enforcement environment; even in non-conflict areas, has not shifted significantly toward the decriminalisation end of the spectrum.

This places Ukraine in the same broad category as Australia: medical access legalised, recreational access prohibited, decriminalisation not formally adopted at national level. The comparison only stretches so far given the very different political and security contexts, but the structural logic is recognisable.

What's still unresolved

I spent a few weekends (in between long loops on the bike out past the Murrumbidgee and some quality time with Trevor the sourdough starter) going through the publicly available Ukrainian regulatory documents and the analyses published by organisations tracking global cannabis law reform. A few things stand out as genuinely unresolved.

First, the list of conditions for which cannabis can be prescribed has been debated and amended repeatedly. Whether the final list is broad or narrow matters enormously to patient access in practice. Second, importation rules are functional in principle but depend on exporting countries' own licensing frameworks, which limits the realistic source countries. Third, there is no clear public timeline for when a fully operational domestic production and dispensing system will exist. The war is the obvious constraint, but regulatory capacity gaps would exist independently of it.

In my view, the 2022 vote was the right structural move and deserves more recognition than it gets in global cannabis policy commentary. But a law that passes with 248 votes and then takes years to become a working system is, in practical terms, still only half done.

Sources

• Cannabis; United Nations Office on Drugs and Crime (UNODC)
• Cannabis policy: status and recent developments, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
• Medicinal cannabis guidance documents, Therapeutic Goods Administration (TGA)
• Cannabis and cannabis-related substances; World Health Organization (WHO)

, Marcus Hale, Regulatory researcher, TGA & access law